Beyond vasodilation: sotatercept and the remodeling hypothesis in hfpef-associated pulmonary hypertension.

A non-vasodilator drug improved breathing, exercise capacity, and heart health in pulmonary hypertension patients without worsening other heart problems—a genuinely new approach.

Phase 2 CADENCE trial data show sotatercept (activin inhibitor targeting vascular remodeling) reduced PVR and improved hemodynamics, 6MWD, NYHA class, and NT-proBNP in HFpEF-associated combined pre/post-capillary pulmonary hypertension without compensatory LV pressure rise, positioning it as the first potential disease-modifying non-vasodilatory agent for this condition.

What the study was

Study design

review

Category

cardiovascular_metabolic

Maturity

clinical

Journal

Heart Failure Reviews

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.